In this study, the modulation of aflatoxin B 1 (AFB 1 ) uptake in rats by administration of the probiotic Lactobacillus rhamnosus GG was demonstrated. Fecal AFB 1 excretion in GG-treated rats was increased via bacterial AFB 1 binding. Furthermore, AFB 1 -associated growth faltering and liver injury were alleviated with GG treatment.Aflatoxins are toxic and carcinogenic fungal metabolites that frequently contaminate staple crops (1). Interventions in aflatoxin exposure focus either on improving crop quality and storage (20) or on altering aflatoxin bioavailability on the individual level, using various adsorbents (5, 18). However, no safe means are presently available to completely protect humans from aflatoxin exposure. Our previous work with lactic acid bacteria revealed that the probiotic strain Lactobacillus rhamnosus strain GG (ATCC 53013) efficiently binds several mycotoxins, including aflatoxin B 1 (AFB 1 ) and aflatoxin M 1 (AFM 1 ), its hydroxylated metabolite, in vitro (6,7,9,10,19). Even though heat-killed bacteria have the highest binding capacities, most studies use viable bacteria, which are more relevant in probiotic products intended for human consumption. Acid, intestinal enzymes, and intestinal mucus were shown not to interfere with AFB 1 binding of this probiotic (6,7,11,12). GG was subsequently demonstrated to bind AFB 1 and to reduce its uptake into intestinal tissue in the ligated duodenal loops of 1-week-old chicks (8). However, this ex vivo method has its limitations in simulating intestinal conditions, and we therefore conducted an in vivo single-dose experiment in rats, investigating the effects of GG on AFB 1 absorption and toxic effects. Five-week-old Han-Wistar rats were kept individually in metabolic cages on standard powdered feed and water ad libitum. After acclimatization, the rats (n ϭ 12/group) received either vehicle (phosphate-buffered saline [PBS]) or probiotic suspension (5 ϫ 10 10 CFU GG/0.5 ml PBS, prepared by directly suspending lyophilized bacteria in PBS) by oral gavage daily for 3 days before and 3 days after a single oral dose of AFB 1 (1.5 mg or 4.8 mol/kg of body weight in dimethyl sulfoxide [Sigma-Aldrich, St. Louis, Mo.]). Four additional rats served as untreated controls. Body weight was recorded at the beginning of the study (prior to GG treatment), on the day of AFB 1 dosing, and at the end of the study. Urine and fecal samples were collected daily, weighed, and stored at Ϫ20°C. At the end of the study, blood samples were taken by cardiac puncture and centrifuged, and the plasma was stored at Ϫ20°C. The experiments were approved by the University of Kuopio animal ethics committee.Extraction of fecal samples was modified from a method developed in our laboratory (17). The samples were mixed with 2.5 volumes of 0.2 M sodium acetate in 10% NaCl, and aliquots (2 ml) were spiked with aflatoxin G 2 (AFG 2 ) (18.6 pmol/sample) as an internal standard and centrifuged (3,000 ϫ g; 15 min; 4°C). The pellets were suspended in 4 ml 80% methanol (in 10% NaCl [vol/vol]) and h...